| Outcome Measures: |
Primary: Changes in glycosylated hemoglobin (HbA1c) from baseline at 24 weeks of treatment, Baseline through Week24 | Secondary: Changes in HbA1c from baseline at 52 weeks of treatment, Baseline through Week52|The percentage of HbA1c≤6.5% and the percentage of HbA1c≤7% at week 24 and 52, Week24 and 52|Change in fasting plasma glucose (FPG) from baseline at week 24 and 52, Baseline through Week24 and 52|Change in weight from baseline at week 24 and 52, Baseline through Week24 and 52|Change in 2h-postprandial plasma glucose (2h-PPG) from baseline at week 24 and 52, Baseline through Week24 and 52|Change in mean 7-point blood glucose curve from baseline at week 24 and 52. Change in mean postprandial blood glucose increment from baseline at week 24 and 52., Baseline through Week24 and 52|Change in blood lipids (triglycerides, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol) from baseline at week 24 and 52, Baseline through Week24 and 52|Proportion of subjects receiving remedial therapy at week 24 and 52, Week24 and 52|Incidence of adverse events, Week-2 through 52|Blood concentrations of TG103, Week 0, 4, 8,16, 24,36, 44,52 and 55|The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (NAb), Week 0, 4, 8,16, 24,36, 44,52 and 55
|
